期刊文献+

Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy 被引量:4

下载PDF
导出
摘要 Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless,the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid deamination, deficiencies in deoxycytidine kinase (DCK), and alterations in nucleoside transporter. On this account, repeated injections with a high concentration of gemcitabine are adopted, leading to severe systemic toxicity to healthy cells. Accordingly, it is highly crucial to fabricate efficient gemcitabine delivery systems to obtain improved therapeutic efficacy of gemcitabine. A large number of gemcitabine pro-drugs were synthesized by chemical modification of gemcitabine to improve its biostability and bioavailability. Besides,gemcitabine-loaded nano-drugs were prepared to improve the delivery efficiency. In this review article, we introduced different strategies for improving the therapeutic performance of gemcitabine by the fabrication of pro-drugs and nano-drugs. We hope this review will provide new insight into the rational design of gemcitabine-based delivery strategies for enhanced cancer therapy.
出处 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2022年第1期35-52,共18页 亚洲药物制剂科学(英文)
基金 supported by the Natural Science Foundation of China (Grant Nos. 52022090, 22005265, 82070739, 81870641) National Key R&D Program of China (Grant No. 2018YFC1106104) Key Research and Development Program of Zhejiang Province (Grant No. 2020C03035) Zhejiang Provincial Natural Science Foundation of China (Grant No. LQ20E030011) Zhejiang Medical Health Science and Technology Program (Grant No. 2021RC061) Zhejiang Provincial Ten Thousand Talents Program (2018R52001)。
  • 相关文献

参考文献6

二级参考文献10

共引文献24

同被引文献11

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部